Bisphosphonate safety and tolerability

被引:4
作者
Body, JJ [1 ]
机构
[1] Univ Libre Bruxelles, Inst Jules Bordet, Dept Internal Med, Brussels, Belgium
关键词
D O I
10.1634/theoncologist.10-5-317
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:317 / 317
页数:1
相关论文
共 3 条
[1]   Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies [J].
Body, JJ ;
Diel, IJ ;
Lichinitzer, M ;
Lazarev, A ;
Pecherstorfer, M ;
Bell, R ;
Tripathy, D ;
Bergstronn, B .
BRITISH JOURNAL OF CANCER, 2004, 90 (06) :1133-1137
[2]   Safety of intravenous and oral bisphosphonates and compliance with dosing regimens [J].
Conte, P ;
Guarneri, V .
ONCOLOGIST, 2004, 9 :28-37
[3]  
HOFFMANN F, 2003, ORAL BONDRONAT IBAND